Based on a survey of 20+ top biopharma organizations, this white paper examines the gap between the high strategic priority of decentralized clinical trials (DCTs) and the practical execution challenges—such as technology integration and ROI tracking—that currently limit their adoption.
Scimitar’s 2023 year-in-review reflects on a pivotal year of growth and impact, highlighting the firm’s commitment to bridging the gap between strategy and execution for global biopharma leaders through innovation in AI, digital transformation, and operational excellence.
This article explains how life science organizations can navigate industry headwinds by adopting a disciplined approach to process improvement, emphasizing the need to clearly define operational workflows and leverage methodologies like Six Sigma and Kaizen to prioritize impactful changes.